The Relative Strength (RS) Rating for AdaptHealth entered a new percentile Friday, as it got a lift from 67 to 74.
IBD's unique rating identifies share price movement with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the last 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history shows that the best-performing stocks often have an RS Rating north of 80 in the early stages of their moves. See if AdaptHealth can continue to rebound and hit that benchmark.
Can You Really Time The Stock Market?
AdaptHealth is trying to complete a consolidation with an 11.90 entry. See if it can clear the breakout price in volume at least 40% above average.
AdaptHealth showed 0% earnings growth in its most recent report. Sales rose 0%.
The company holds the No. 3 rank among its peers in the Medical-Outpatient/Home Care industry group. Encompass Health is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
